osteoporosis
Amgen files high earnings for Q1
April 22, 2015Sales and Marketing AMG 334, Amgen, Corlanor, Kyprolis, Prolia, Q1, Xgeva, brodalumab, myeloma, osteoporosis
Amgen has boosted its first quarter profit by 51% due to surging drug sales and ongoing cuts that paved the …
UCB and Amgen’s osteoporosis drug shows promise
April 21, 2011Research and Development Amgen, UCB, osteoporosis
Amgen and UCB have announced strong results from a phase II study of their new postmenopausal osteoporosis treatment. Most existing …
FDA warns of bisphosphonates fracture risk
October 20, 2010Sales and Marketing Boniva, Fosamax, Reclast, actonel, bisphosphonates, osteoporosis
The FDA has ordered a label change for a number of osteoporosis drugs after concerns their long-term use raises the …
Trial shows long-term benefits of Novartis’ Aclasta
October 18, 2010Research and Development, Sales and Marketing Novartis, aclasta, osteoporosis
Novartis has published new data at the annual meeting of the American Society for Bone and Mineral Research in Toronto …
Digital Pharma: NHS Direct pilots online treatment aids
June 11, 2010Medical Communications NHS, NHS Direct, osteoporosis, patient information, prostate cancer
NHS Direct is piloting online decision aids to help patients suffering from osteoporosis or prostate cancer make informed healthcare choices. …
Warner Chilcott gets Actonel lift
April 6, 2010Sales and Marketing Sanofi, Warner Chilcott, actonel, osteoporosis
Warner Chilcott has assumed all commercial responsibility for its osteoporosis drug Actonel in the US. Sanofi-Aventis has agreed to pass …
Servier fails to overturn NICE osteoporotic guidance
February 2, 2010Sales and Marketing NICE, Servier, osteoporosis
Servier’s challenge to NICE guidance on preventing osteoporotic fractures has proved unsuccessful, with the watchdog’s original decision still standing. This …
Osteoporosis drug Aclasta approved for use in men
October 2, 2008Sales and Marketing Novartis, aclasta, osteoporosis
Osteoporosis treatment Aclasta has been approved for an extended indication in the European Union.Novartis’ once-yearly infusion has now been given …
